Tatva Chintan Pharma Chem Limited reported a 54.8% year-on-year increase in consolidated net profit to ₹159.81 million for the quarter ended 30 June 2026, driven by higher operational income. Total income from operations rose 43% to ₹1,671 million from ₹1,168.64 million in the same period last year. EBITDA stood at ₹323 million, representing an 86% growth year-on-year and a 15% improvement over the previous quarter. The company’s earnings per share (EPS) on a consolidated basis improved to ₹6.83 for the quarter, compared to ₹2.84 in the corresponding period of the previous year.

The Board of Directors approved the financial results during its meeting held on 17 July 2026. Additionally, the Board approved the establishment of a new greenfield manufacturing facility involving an investment of approximately ₹200 crores. The groundbreaking ceremony is scheduled for 20 July 2026. The proposed facility is designed as a future-ready manufacturing platform to support the commercialization of new products and provide capacity for the company's next phase of growth. Management expects the facility to generate revenue of around ₹300 crores at peak utilization, targeting an asset turnover ratio of 1.2x to 1.5x.

Segment-wise Performance

Phase Transfer Catalysts contributed ₹428 million in revenue, a 38% growth quarter-on-quarter and 47% increase year-on-year. Structure Directing Agents reported ₹578 million in revenue, reflecting a 10% growth quarter-on-quarter and a 47% increase year-on-year. Pharma & Agro Intermediates and Specialty Chemicals delivered ₹584 million in revenue, a 63% growth quarter-on-quarter and a 25% growth year-on-year. Electrolyte Salts achieved ₹63 million in revenue, recording a 52% decline sequentially and a growth of 76% year-on-year.

Consolidated Financial Results

Standalone Financial Results

The extract of the financial results was filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tatva Chintan Pharma Chem Ltd has scheduled a virtual one-on-one meeting with Alchemy Capital Management Pvt. Ltd. on July 28, 2026. The interaction aims to engage with the investor based on publicly available information, ensuring no unpublished price sensitive information (UPSI) is disclosed during the session.

The company clarified that discussions will be restricted to information already accessible to the public. The schedule was intimated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company noted that the schedule is subject to change. The information regarding the meeting is available on the company's website.